Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report
Lambert, Nicolas; El Moussaoui, Majdouline; Ritacco, Carolineet al.
[en] Treating patients with cancer complicated by severe opportunistic infections is particularly challenging since classical cancer treatments, such as chemotherapy, often induce profound immune suppression and, as a result, may favor infection progression. Little is known about the potential place of immune checkpoint inhibitors in these complex situations. Here, we report a 66-year-old man who was concomitantly diagnosed with non-small cell lung cancer and progressive multifocal leukoencephalopathy. The patient was treated with anti-PD-L1 antibody atezolizumab, which allowed effective control of both lung cancer and progressive multifocal leukoencephalopathy, as demonstrated by the patient’s remarkable neurologic clinical improvement, JC viral load reduction in his cerebrospinal fluid, regression of the brain lesions visualized through MRI, and the strict radiological stability of his cancer. In parallel, treatment with atezolizumab was associated with biological evidence of T-cell reinvigoration. Hence, our data suggest that immune checkpoint inhibitors may constitute a treatment option for patients with cancer complicated by severe opportunistic infections.
Disciplines :
Immunology & infectious disease
Author, co-author :
Lambert, Nicolas ; Université de Liège - ULiège > GIGA > GIGA Stem Cells - Molecular Regulation of Neurogenesis ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
El Moussaoui, Majdouline ; Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Maladies infectieuses et médecine interne générale ; Université de Liège - ULiège > GIGA > GIGA I3 - Immunology & Infectious Diseases
MOISE, Martin ; Université de Liège - ULiège > GIGA ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiodiagnostic
PAULUS, Astrid ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
DELVENNE, Philippe ; Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology ; Université de Liège - ULiège > Département des sciences précliniques MI > Anatomie et cytologie pathologiques
BARON, Frédéric ; Université de Liège - ULiège > GIGA > GIGA I3 - Hematology ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
SADZOT, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
MAQUET, Pierre ; Université de Liège - ULiège > GIGA > GIGA CRC In vivo Imaging - Sleep and chronobiology ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Language :
English
Title :
Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report
Publication date :
03 May 2022
Journal title :
Frontiers in Immunology
eISSN :
1664-3224
Publisher :
Frontiers Research Foundation, Lausanne, Switzerland
Siegel RL Miller KD Fuchs HE Jemal A. Cancer Statistics, 2021. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654
Cortese I Muranski P Enose-Akahata Y Ha SK Smith B Monaco MC et al. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med (2019) 380(17):1597–605. doi: 10.1056/NEJMoa1815039
Lambert N Dauby S Dive D Sadzot B Maquet P. Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy. Emerg Infect Dis (2022) 28(1):253–6. doi: 10.3201/eid2801.204809
Cortese I Reich DS Nath A. Progressive Multifocal Leukoencephalopathy and the Spectrum of JC Virus-Related Disease. Nat Rev Neurol (2021) 17(1):37–51. doi: 10.1038/s41582-020-00427-y
Berger JR Aksamit AJ Clifford DB Davis L Koralnik IJ Sejvar JJ et al. PML Diagnostic Criteria: Consensus Statement From the AAN Neuroinfectious Disease Section. Neurol (2013) 80(15):1430–8. doi: 10.1212/WNL0b013e31828c2fa1
Beck ES Cortese I. Checkpoint Inhibitors for the Treatment of JC Virus-Related Progressive Multifocal Leukoencephalopathy. Curr Opin Virol (2020) 40:19–27. doi: 10.1016/j.coviro.2020.02.005
Wherry EJ Kurachi M. Molecular and Cellular Insights Into T Cell Exhaustion. Nat Rev Immunol (2015) 15(8):486–99. doi: 10.1038/nri3862
Pawlitzki M Schneider-Hohendorf T Rolfes L Meuth SG Wiendl H Schwab N et al. Ineffective Treatment of PML With Pembrolizumab: Exhausted Memory T-Cell Subsets as a Clue? Neurol Neuroimmunol Neuroinflamm (2019) 6(6):e627. doi: 10.1212/NXI.0000000000000627
Lambert N El Moussaoui M Maquet P. Immune Checkpoint Inhibitors for Progressive Multifocal Leukoencephalopathy: Identifying Relevant Outcome Factors. Eur J Neurol (2021) 28(11):3814–9. doi: 10.1111/ene.15021
Grimaldi D Pradier O Hotchkiss RS Vincent JL. Nivolumab Plus Interferon-γ in the Treatment of Intractable Mucormycosis. Lancet Infect Dis (2017) 17(1):18. doi: 10.1016/S1473-3099(16)30541-2
Banck JC Mueller N Mellinghoff SC Thelen M Fraccaroli A Blumemberg V et al. Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection. Hemasphere (2021) 5(3):e530. doi: 10.1097/HS9.0000000000000530
Locati LD Serafini MS Carenzo A Canevari S Perrone F Orlandi E et al. Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report. Front Oncol (2022) 11:799453. doi: 10.3389/fonc.2021.799453